Efficacy of Intravenous Immunoglobulin for Systemic Manifestations of Dermatomyositis Beyond Muscular and Cutaneous: Sub-analysis of the ProDERM Study

By afschroeder • July 6, 2025

Aggarwal R, Schessl J, Bata-Csörgő Z, Dimachkie MM, Griger Z, Moiseev S, Oddis CV, Schiopu E, Vencovský J, Clodi E, Levine T, Charles-Schoeman C; ProDERM investigators. Efficacy of Intravenous Immunoglobulin for Systemic Manifestations of Dermatomyositis Beyond Muscular and Cutaneous: Sub-analysis of the ProDERM Study. Rheumatol Ther. 2025 Jul 5. doi: 10.1007/s40744-025-00775-5. Epub ahead of print. PMID: 40616720.

Tags: Arthralgia, Arthritis, Constitutional, Dermatomyositis, gastrointestinal, Immunoglobulins, Intravenous, Octagam, Publications, pulmonary, Rheumatology, Skeletal

The role of declining therapy volumes in skilled nursing facility outcomes: a mediation analysis

Prusynski RA, Humbert A, Amaravadi H, Burke RE, Saliba D, Leland NE, Freburger J, Mroz TM. The role of declining therapy volumes in skilled nursing[...]

Bloodstream Infections Among Veterans With Cardiac Implantable Electronic Devices: Source Identification and Intervention Strategies

Basnet D, Golenbock S, Strymish JM, Mull HJ, Lamkin RP, Shin M, Harvey K, Karchmer AW, Branch-Elliman W. Bloodstream Infections Among Veterans With Cardiac Implantable[...]

FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma

Corren J, Reid F, Moate R, Jimenez E, Sadiq MW, Williams A, Rytelewski M, Cameron-Christie S, Muthas D, Georgi B, Brooks D, Lindqvist E, Kell[...]